BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.53 CNY | -1.93% |
|
-0.59% | +1.51% |
| May. 07 | China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7% | MT |
| May. 07 | BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3% | MT |
| Sales 2022 | 1.02B 140M | Sales 2023 | 1.18B 163M | Capitalization | 14.79B 2.04B |
|---|---|---|---|---|---|
| Net income 2022 | 240M 33.14M | Net income 2023 | 202M 27.9M | EV / Sales 2022 | 10.2 x |
| Net Debt 2022 | 791M 109M | Net Debt 2023 | 1.16B 160M | EV / Sales 2023 | 13.5 x |
| P/E ratio 2022 |
38.9
x | P/E ratio 2023 |
72.9
x | Employees | 1,155 |
| Yield 2022 |
0.51% | Yield 2023 |
0.27% | Free-Float | 48.25% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.93% | ||
| 1 week | -0.59% | ||
| 1 month | +14.65% | ||
| 3 months | +16.88% | ||
| 6 months | -0.28% | ||
| Current year | +1.51% |
1 week
34.60
38.02
1 month
31.0839.16
Current year
19.6339.16
1 year
17.8146.88
3 years
17.1048.49
5 years
17.1072.43
10 years
17.1072.43
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Dong Yuan
CEO | Chief Executive Officer | 54 | 01-10-25 |
Yuan Lai Zou
DFI | Director of Finance/CFO | 53 | 10-12-31 |
Fan Hang
BRD | Director/Board Member | 38 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Dong Yuan
CEO | Chief Executive Officer | 54 | 01-10-25 |
Simon Lü
BRD | Director/Board Member | 56 | 17-05-12 |
Yang Qing Huang
BRD | Director/Board Member | 43 | 08-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 35.53 | -1.93% | 10,452,960 |
| 24-05-30 | 36.23 | -0.44% | 4,645,658 |
| 24-05-29 | 36.39 | -2.05% | 6,201,554 |
| 24-05-28 | 37.15 | +0.95% | 6,576,787 |
| 24-05-27 | 36.8 | +2.97% | 8,412,680 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes
BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 2.07B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- 688166 Stock
